| Primary |
| Product Used For Unknown Indication |
15.9% |
| Bacteraemia |
10.2% |
| Osteomyelitis |
10.2% |
| Staphylococcal Infection |
8.9% |
| Infection |
7.6% |
| Arthritis Bacterial |
4.5% |
| Febrile Neutropenia |
4.5% |
| Infection Prophylaxis |
4.5% |
| Cellulitis |
3.8% |
| Enterococcal Infection |
3.8% |
| Hyperlipidaemia |
3.8% |
| Endocarditis Staphylococcal |
3.2% |
| Soft Tissue Infection |
3.2% |
| Staphylococcal Bacteraemia |
3.2% |
| Arthritis Infective |
2.5% |
| Skin Infection |
2.5% |
| Abscess |
1.9% |
| Post Procedural Infection |
1.9% |
| Staphylococcal Osteomyelitis |
1.9% |
| Staphylococcal Sepsis |
1.9% |
|
| Rhabdomyolysis |
21.5% |
| Eosinophilic Pneumonia |
15.7% |
| Blood Creatine Phosphokinase Increased |
14.9% |
| Anaphylactic Shock |
4.1% |
| Dyspnoea |
4.1% |
| Myalgia |
4.1% |
| Pneumonitis |
4.1% |
| Pruritus |
3.3% |
| Pyrexia |
3.3% |
| Rash |
3.3% |
| Thrombocytopenia |
3.3% |
| Infection |
2.5% |
| Liver Function Test Abnormal |
2.5% |
| Renal Failure |
2.5% |
| Vomiting |
2.5% |
| Alveolitis Allergic |
1.7% |
| Impaired Healing |
1.7% |
| Interstitial Lung Disease |
1.7% |
| Pain |
1.7% |
| Pneumonia |
1.7% |
|
| Secondary |
| Product Used For Unknown Indication |
30.8% |
| Drug Use For Unknown Indication |
14.1% |
| Endocarditis |
9.1% |
| Staphylococcal Infection |
6.4% |
| Osteomyelitis |
5.8% |
| Endocarditis Bacterial |
3.8% |
| Bacteraemia |
3.5% |
| Cellulitis |
3.0% |
| Pseudomonas Infection |
2.9% |
| Osteomyelitis Chronic |
2.7% |
| Prophylaxis |
2.6% |
| Soft Tissue Infection |
2.4% |
| Pneumonia |
1.9% |
| Staphylococcal Sepsis |
1.8% |
| Arthropathy |
1.6% |
| Immunosuppression |
1.6% |
| Thrombosis Prophylaxis |
1.6% |
| Antibiotic Therapy |
1.4% |
| Diarrhoea |
1.4% |
| Infection |
1.4% |
|
| Anaphylactic Shock |
13.2% |
| Pancytopenia |
7.9% |
| Rhabdomyolysis |
7.9% |
| Drug Interaction |
7.0% |
| Pneumonia |
6.1% |
| Renal Failure |
5.3% |
| Staphylococcal Sepsis |
5.3% |
| Blood Creatinine Increased |
4.4% |
| Death |
4.4% |
| Drug Ineffective |
4.4% |
| White Blood Cell Count Increased |
4.4% |
| Atrial Fibrillation |
3.5% |
| Drug Hypersensitivity |
3.5% |
| Drug Rash With Eosinophilia And Systemic Symptoms |
3.5% |
| Megacolon |
3.5% |
| Rash |
3.5% |
| Renal Failure Acute |
3.5% |
| Thrombocytopenia |
3.5% |
| Dyspnoea |
2.6% |
| Infection |
2.6% |
|
| Concomitant |
| Product Used For Unknown Indication |
53.6% |
| Drug Use For Unknown Indication |
27.2% |
| Prophylaxis |
2.9% |
| Acute Myeloid Leukaemia |
2.1% |
| Sepsis |
1.8% |
| Pain |
1.7% |
| Multiple Myeloma |
1.4% |
| Infection Prophylaxis |
1.2% |
| Infection |
1.0% |
| Diffuse Large B-cell Lymphoma |
0.8% |
| Hypertension |
0.8% |
| Nausea |
0.7% |
| Insomnia |
0.6% |
| Acute Lymphocytic Leukaemia |
0.6% |
| Breast Cancer |
0.6% |
| Cardiac Operation |
0.6% |
| Constipation |
0.6% |
| Staphylococcal Infection |
0.6% |
| Antibiotic Therapy |
0.6% |
| Diabetes Mellitus |
0.6% |
|
| Vomiting |
10.6% |
| Sepsis |
9.8% |
| Respiratory Failure |
7.6% |
| Tachycardia |
7.6% |
| Thrombocytopenia |
6.8% |
| Septic Shock |
5.3% |
| Staphylococcal Infection |
5.3% |
| Nephropathy Toxic |
4.5% |
| Renal Failure |
4.5% |
| White Blood Cell Count Increased |
4.5% |
| Drug Rash With Eosinophilia And Systemic Symptoms |
3.8% |
| Syncope |
3.8% |
| Thrombosis |
3.8% |
| White Blood Cell Count Decreased |
3.8% |
| Anhedonia |
3.0% |
| Oxygen Saturation Decreased |
3.0% |
| Pyrexia |
3.0% |
| Renal Failure Acute |
3.0% |
| Subarachnoid Haemorrhage |
3.0% |
| Tubulointerstitial Nephritis |
3.0% |
|
| Interacting |
| Product Used For Unknown Indication |
42.3% |
| Endocarditis Bacterial |
19.2% |
| Infection |
12.5% |
| Antibiotic Therapy |
5.8% |
| Chronic Hepatitis C |
5.8% |
| Evidence Based Treatment |
5.8% |
| Aplastic Anaemia |
4.8% |
| Acute Promyelocytic Leukaemia |
1.9% |
| Analgesic Therapy |
1.0% |
| Drug Use For Unknown Indication |
1.0% |
|
| Drug Interaction |
46.2% |
| Rhabdomyolysis |
23.1% |
| Agranulocytosis |
7.7% |
| Drug Hypersensitivity |
7.7% |
| Myositis |
7.7% |
| No Adverse Event |
7.7% |
|
